Anti-programmed cell death-1 (PD-1) antibodies can cause thyroid dysfunction. However, no predictive biomarkers enabling stratification of thyroid dysfunction risk have been identified.
A total of 209 patients treated with an anti-PD-1 antibody were evaluated for anti-thyroid antibodies at baseline and prospectively for thyroid function every 6 weeks for 24 weeks after treatment initiation, and then observed until the visits stopped. Thyroid ultrasonography was performed if the patient was positive for anti-thyroid antibodies at baseline.
Of the 209 patients, 19 (9.1%) developed thyroid dysfunction (destructive thyroiditis or hypothyroidism). The cumulative incidence of thyroid dysfunction was significantly higher in patients who were positive vs. negative for anti-thyroid antibodies (15/44 [34.1%] vs. 4/165 [2.4%], p < 0.001). Forty-two patients positive for anti-thyroid antibodies at baseline were divided into two groups according to the presence of an irregular echo pattern. The cumulative incidence of thyroid dysfunction was significantly higher in those with an irregular vs. a regular echo pattern (13/23 [56.5%] vs. 1/19 [5.3%], p = 0.001). None of the patients developed thyroid dysfunction after the initial 24-week period.
The risk of thyroid dysfunction induced by anti-PD-1 antibodies can be predicted by evaluation of anti-thyroid antibodies and the thyroid echo pattern at baseline.
Subscribe to Journal
Get full journal access for 1 year
only $32.88 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015).
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320–330 (2015).
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823–1833 (2016).
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627–1639 (2015).
Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 378, 158–168 (2018).
González-Rodríguez, E. & Rodríguez-Abreu, D., (GETICA) SGfCI-B. Immune checkpoint inhibitors: review and management of endocrine adverse events. Oncologist 21, 804–816 (2016).
Chang, L. S., Barroso-Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B. & Min, L. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr. Rev. 40, 17–65 (2019).
Kobayashi, T., Iwama, S., Yasuda, Y., Okada, N., Tsunekawa, T., Onoue, T. et al. Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study. J. Endocr. Soc. 2, 241–251 (2018).
Hayashi, N., Tamaki, N., Konishi, J., Yonekura, Y., Senda, M., Kasagi, K. et al. Sonography of Hashimoto’s thyroiditis. J. Clin. Ultrasound 14, 123–126 (1986).
Yoshida, A., Adachi, T., Noguchi, T., Urabe, K., Onoyama, S., Okamura, Y. et al. Echographic findings and histological feature of the thyroid: a reverse relationship between the level of echo-amplitude and lymphocytic infiltration. Endocrinologia. Japonica. 32, 681–690 (1985).
Marcocci, C., Vitti, P., Cetani, F., Catalano, F., Concetti, R. & Pinchera, A. Thyroid ultrasonography helps to identify patients with diffuse lymphocytic thyroiditis who are prone to develop hypothyroidism. J. Clin. Endocrinol. Metab. 72, 209–213 (1991).
Rago, T., Chiovato, L., Grasso, L., Pinchera, A. & Vitti, P. Thyroid ultrasonography as a tool for detecting thyroid autoimmune diseases and predicting thyroid dsfunction in apparently healthy subjects. J. Endocrinol. Invest. 24, 763–769 (2001).
Vejbjerg, P., Knudsen, N., Perrild, H., Laurberg, P., Pedersen, I. B., Rasmussen, L. B. et al. The association between hypoechogenicity or irregular echo pattern at thyroid ultrasonography and thyroid function in the general population. Eur. J. Endocrinol. 155, 547–552 (2006).
Torimoto, K., Okada, Y., Nakayamada, S., Kubo, S. & Tanaka, Y. Anti-PD-1 antibody therapy induces Hashimoto’s disease with an increase in peripheral blood follicular helper T cells. Thyroid 27, 1335–1336 (2017).
Gay, S., Rossi, G., Corica, G., Graziani, G., Genova, C., Rijavec, E. et al. Can baseline endocrinological examination and thyroid ultrasound predict the development of thyroid disease in immunotherapy-treated patients? Results from a prospective, single-center, open-label study. Endocrine; https://doi.org/10.1007/s12020-019-01854-8; e-pub ahead of print 7 March 2019 (2019).
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 36, 1714–1768 (2018).
Higham, C. E., Olsson-Brown, A., Carroll, P., Cooksley, T., Larkin, J., Lorigan, P. et al. SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr. Connect. 7, G1–G7 (2018).
Arima, H., Iwama, S., Inaba, H., Ariyasu, H., Makita, N., Otsuki, M. et al. Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society. Endocri. J. 66, 581–586 (2019).
Kimbara, S., Fujiwara, Y., Iwama, S., Ohashi, K., Kuchiba, A., Arima, H. et al. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. Cancer Sci. 109, 3583–3590 (2018).
Dayan, C. M. & Daniels, G. H. Chronic autoimmune thyroiditis. N. Engl. J. Med. 335, 99–107 (1996).
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J. L., Fong, L. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 376, 1015–1026 (2017).
de Filette, J., Jansen, Y., Schreuer, M., Everaert, H., Velkeniers, B., Neyns, B. et al. Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. J. Clin. Endocrinol. Metab. 101, 4431–4439 (2016).
Delivanis, D. A., Gustafson, M. P., Bornschlegl, S., Merten, M. M., Kottschade, L., Withers, S. et al. Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms. J. Clin. Endocrinol. Metab. 102, 2770–2780 (2017).
Osorio, J. C., Ni, A., Chaft, J. E., Pollina, R., Kasler, M. K., Stephens, D. et al. Antibody-mediated thyroid dysfunction during t-cell checkpoint blockade in patients with non-small cell lung cancer. Ann. Oncol. 28, 583–589 (2017).
Neppl, C., Kaderli, R. M., Trepp, R., Schmitt, A. M., Berger, M. D., Wehrli, M. et al. Histology of nivolumab-induced thyroiditis. Thyroid 12, 1727–1728 (2018).
Bogner, U., Schleusener, H. & Wall, J. R. Antibody-dependent cell mediated cytotoxicity against human thyroid cells in Hashimoto’s thyroiditis but not Graves’ disease. J. Clin. Endocrinol. Metab. 59, 734–738 (1984).
Bogner, U., Hegedus, L., Hansen, J. M., Finke, R. & Schleusener, H. Thyroid cytotoxic antibodies in atrophic and goitrous autoimmune thyroiditis. Eur. J. Endocrinol. 132, 69–74 (1995).
Menzies, A. M., Johnson, D. B., Ramanujam, S., Atkinson, V. G., Wong, A. N. M., Park, J. J. et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann. Oncol. 28, 368–376 (2017).
Borodic, G., Hinkle, D. M. & Cia, Y. Drug-induced graves disease from CTLA-4 receptor suppression. Ophthal. Plast. Reconstr. Surg. 27, e87–e88 (2011).
Borodic, G. & Hinkle, D. M. Ipilimumab-induced orbital inflammation resembling Graves disease with subsequent development of systemic hyperthyroidism from CTLA-4 receptor suppression.pdf. Ophthal. Plast. Reconstr. Surg. 30, 83 (2014).
Sabini, E., Sframeli, A. & Marino M. A case of drug-induced Graves’ orbitopathy after combination therapy with tremelimumab and durvalumab. J. Endocrinol. Invest.; https://doi.org/10.1007/s40618-018-0906-0; e-pub ahead of print 29 May 2018 (2018).
Park, E. S. Y., Rabinowits, G., Hamnvik, O. R. & Dagi, L. R. A case of Graves’ ophthalmopathy associated with pembrolizumab (Keytruda) therapy. J AAPOS; https://doi.org/10.1016/j.jaapos.2018.01.006; e-pub ahead of print 8 April 2018 (2018).
Sato, K., Akamatsu, H., Murakami, E., Sasaki, S., Kanai, K. Hayata, A. et al. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer 115, 71–74 (2018).
Lisberg, A., Tucker, D. A., Goldman, J. W., Wolf, B., Carroll, J., Hardy, A. et al. Treatment-related adverse events predict improved clinical outcome in NSCLC patients on KEYNOTE-001 at a single center. Cancer Immunol. Res.; https://doi.org/10.1158/2326-6066.CIR-17-0063; e-pub ahead of print 30 January 2018 (2018).
Haratani, K., Hayashi, H., Chiba, Y., Kudo, K., Yonesaka, K., Kato, R. et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol. 4, 374–378 (2018).
Ricciuti, B., Genova, C., De Giglio, A., Bassanelli, M., Dal Bello, M. G., Metro, G. et al. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J. Cancer Res. Clin. Oncol.; https://doi.org/10.1007/s00432-018-2805-3; e-pub ahead of print 7 December 2018 (2018).
Ethics approval and consent to participate
This study was approved by the Ethical Committee of Nagoya University Hospital (approval number: 2015-0273), and was performed in accordance with the Declaration of Helsinki. All enrolled patients provided written informed consent before any of the study-specific procedures were performed. Clinical trial information: www.umin.ac.jp no. UMIN000019024 (registered September 15, 2015).
Consent to publish
We obtained consent for publication from all patients in this study.
All data included in this study are available upon request, sent to the corresponding author.
S.I. is a consultant/advisory board member for endocrinological adverse events at Ono Pharmaceutical Company and Bristol-Myers Squibb, and receives fees for presentations, consulting and advising, and the writing of published materials from Ono Pharmaceutical Company, Bristol-Myers Squibb and MSD K.K. T.H. receives personal fees from Ono Pharmaceutical Company, Bristol-Myers Squibb and MSD K.K. M.M. receives personal fees from Ono Pharmaceutical Company, Bristol-Myers Squibb and MSD K.K. M.N. receives a grant from Bristol-Myers Squibb. Y.K. receives grants and personal fees from Ono Pharmaceutical Company, Bristol-Myers Squibb and MSD K.K. M.F. receives personal fees from Ono Pharmaceutical Company, and MSD K.K. H.K. receives grants and personal fees from Ono Pharmaceutical Company and Bristol-Myers Squibb, and MSD K.K. M.G. receives grants from Ono Pharmaceutical Company. Y.A. receives grants from Ono Pharmaceutical Company and personal fees from Ono Pharmaceutical Company and Bristol-Myers Squibb. M.Ak. receives grants from Ono Pharmaceutical Company, and MSD K.K. Y.H. receives grants and personal fees from Ono Pharmaceutical Company and Bristol-Myers Squibb, and MSD K.K. H.A. receives grants from Ono Pharmaceutical Company. MSD K.K. receives personal fees from Ono Pharmaceutical Company and Bristol-Myers Squibb. The remaining authors have nothing to disclose.
The authors declare no funding support.
Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Okada, N., Iwama, S., Okuji, T. et al. Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study. Br J Cancer 122, 771–777 (2020). https://doi.org/10.1038/s41416-020-0736-7
The Journal of Allergy and Clinical Immunology: In Practice (2020)
Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study
Journal for ImmunoTherapy of Cancer (2020)